EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials

Liyun Jiang, Peter F Thall, Fangrong Yan iD, Scott Kopetz, Ying Yuan iD

Clinical Trials · 2023-10 · 20 (5) · 486-496

DOI: 10.1177/17407745231176445 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Trials, online erschienen am 14.06.2023. Verfasst von Liyun Jiang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: Research Design. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Randomized controlled trials are considered the gold standard for evaluating experimental treatments but often require large sample sizes. Single-arm trials require smaller sample sizes but are subject to bias when using historical control data for comparative inferences. This article presents a Bayesian adaptive synthetic-control design that exploits historical control data to create a hybrid of a single-arm trial and a randomized controlled trial.

Methods

The Bayesian adaptive synthetic control design has two stages. In stage 1, a prespecified number of patients are enrolled in a single arm given the experimental treatment. Based on the stage 1 data, applying propensity score matching and Bayesian posterior prediction methods, the usefulness of the historical control data for identifying a pseudo sample of matched synthetic-control patients for making comparative inferences is evaluated. If a sufficient number of synthetic controls can be identified, the single-arm trial is continued. If not, the trial is switched to a randomized controlled trial. The performance of The Bayesian adaptive synthetic control design is evaluated by computer simulation.

Results

The Bayesian adaptive synthetic control design achieves power and unbiasedness similar to a randomized controlled trial but on average requires a much smaller sample size, provided that the historical control data patients are sufficiently comparable to the trial patients so that a good number of matched controls can be identified in the historical control data. Compared to a single-arm trial, The Bayesian adaptive synthetic control design yields much higher power and much smaller bias.

Conclusion

The Bayesian adaptive synthetic-control design provides a useful tool for exploiting historical control data to improve the efficiency of single-arm phase II clinical trials, while addressing the problem of bias when comparing trial results to historical control data. The proposed design achieves power similar to a randomized controlled trial but may require a substantially smaller sample size.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignHumansBayes TheoremBiasComputer SimulationRandomized Controlled Trials as TopicSample SizeClinical Trials, Phase II as Topic

Stichwörter der Autor:innen

Bayesian adaptive designReal-world dataaugmented controlhistorical datarandomized controlled trials

Autor:innen und Institutionen

  • Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, China.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

ORCID-Profile: Fangrong Yan, Ying Yuan

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Jiang, L., Thall, P. F., Yan, F., Kopetz, S., & Yuan, Y. (2023). BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials. Clinical Trials, 20(5), 486-496. https://doi.org/10.1177/17407745231176445

Vancouver

Jiang L, Thall PF, Yan F, Kopetz S, Yuan Y. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials. Clinical Trials. 2023;20(5):486-496. doi:10.1177/17407745231176445

BibTeX
@article{Jiang2023,
  author = {Jiang, Liyun and Thall, Peter F and Yan, Fangrong and Kopetz, Scott and Yuan, Ying},
  title = {BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials},
  journal = {Clinical Trials},
  year = {2023},
  volume = {20},
  number = {5},
  pages = {486--496},
  doi = {10.1177/17407745231176445}
}
Kostenlos starten →